Cell Medica, a London, UK-based cellular immunotherapy company, closed a £60m Series C funding round.
Backers included existing investors Touchstone Innovations, funds managed by Invesco Perpetual, and funds managed by Woodford Investment Management.
The company intends to use the funds to continue to progress its three proprietary technology platforms for cell-based immunotherapy products.
Led by Gregg Sando, Chief Executive Officer, CEO, Cell Medica is a cellular therapeutics company engaged in the development, manufacturing and marketing of cellular immunotherapy products for the treatment of cancer. It is developing a range of cell-based immunotherapy products using three proprietary technology platforms including activated cytotoxic T cells, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs).
The lead oncology product, baltaleucel-T (CMD-003), is currently under investigation in the CITADEL Phase 2 clinical trial for the treatment of patients with advanced lymphomas associated with the Epstein Barr virus. Over the last year, Cell Medica has expanded its technology base through two strategic collaborations and the acquisition of Delenex Therapeutics. The company has established a product development partnership with Baylor College of Medicine to develop genetically engineered chimeric antigen receptors (CARs) to reprogramme human immune cells to recognise and kill cancer cells while also preventing cancer escape mechanisms. This partnership will explore the use of NKT cells to target solid tumors.